Cryoport, Inc. (NASDAQ:CYRX - Free Report) - Stock analysts at Leerink Partnrs issued their Q4 2026 earnings per share estimates for Cryoport in a report released on Wednesday, April 16th. Leerink Partnrs analyst P. Souda forecasts that the company will earn ($0.16) per share for the quarter. The consensus estimate for Cryoport's current full-year earnings is ($0.99) per share.
Several other equities analysts have also weighed in on the stock. Roth Mkm restated a "buy" rating and set a $15.00 price objective on shares of Cryoport in a research report on Tuesday, April 1st. Guggenheim reissued a "buy" rating and set a $10.00 price objective on shares of Cryoport in a research note on Wednesday, April 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of Cryoport in a report on Wednesday, April 16th. Finally, UBS Group boosted their price objective on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $11.67.
Read Our Latest Research Report on Cryoport
Cryoport Price Performance
Cryoport stock traded down $0.03 during trading hours on Friday, hitting $5.52. 358,425 shares of the company traded hands, compared to its average volume of 543,855. The firm's 50-day simple moving average is $5.96 and its two-hundred day simple moving average is $6.99. The firm has a market cap of $275.50 million, a P/E ratio of -1.63 and a beta of 1.81. Cryoport has a 1-year low of $4.58 and a 1-year high of $17.41. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.
Cryoport (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the prior year, the business earned ($0.29) earnings per share.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after purchasing an additional 2,120 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Cryoport during the 4th quarter valued at $51,000. Avanza Fonder AB acquired a new position in shares of Cryoport in the 4th quarter valued at $64,000. Quarry LP acquired a new stake in shares of Cryoport during the fourth quarter worth $69,000. Finally, GAMMA Investing LLC increased its holdings in Cryoport by 4,434.6% in the first quarter. GAMMA Investing LLC now owns 14,556 shares of the company's stock valued at $89,000 after purchasing an additional 14,235 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company's stock.
Insider Activity at Cryoport
In related news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares of the company's stock, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 19,830 shares of company stock worth $118,353 over the last three months. Company insiders own 10.10% of the company's stock.
About Cryoport
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Articles
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
